This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Bristol-Myers Squibb announcing positive interim data from the CheckMate 650 assessing Opdivo (nivolumab) and Yervoy (ipilimumab) in metastatic castration-resistant prostate cancer (mCRPC); Janssen presenting preliminary data from the Phase II GALAHAD study assessing niraparib in patients with mCRCP at the American Society of Clinical Oncology Genitourinary Cancers Symposium (14-16 February 2019) In San Francisco, CA, USA; Onoclogy Ventures announcing that the first patient had been dosed in a Phase II study of LiPlaCis, its liposomal formulation of cisplatin.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved